LY SOZY ME is an ubiquitous e nzym e found in m os t bio logical s ecr etion s and le ukocyte s . Th is s tudy w as aim e d at in ves tigatin g its in teraction w ith oth e r in flam m ato ry m ediators on m ucos a s ur faces , p articularly th e com p lem e nt s ys tem . Ly s o zym e h as be en s h ow n in o ur p re s en t s tudy , to in h ibit th e h aem o lytic activity of s erum com p lem e nt in a dos e-dep en de nt fa s h ion , w h en tes ted w ith in th e levels pr e s en t in n or m al and in flam ed bre as t-m ilk s am p les , and oth e r m ucos al s ecr etion s . Th is r ep r es en ts a ne w an tiin flam m ato ry action o f lys o zym e in r elatio n to th e s e rum co m p le m en t, and th e e x act m o de of th e in te ractio n ne ed furth e r s tudie s .
Introduction
Lysozyme is an acid-and heat-stable enzyme that is abundant in the breast-milk and in most other mucosal body-fluids. 1 Lysozyme catalyses the hydrolysis of b (-1,4-) linkage be tw ee n N-ac etylglucosamine and N-ace tylmuramic ac id in the bacte rial c ell w all. The enzyme lyse s mostly Gram-positive and a few Gram-ne gative bacte ria or induce s their aggregation. 2 In addition, it possesses promine nt anti-inflammatory propertie s.
Lysozyme has be e n show n to inhibit che motax is of activated leukoc yte s. Other anti-inflammatory functions of lysozyme include inhibition of mitogeninduc ed lymphoblastogene sis and autologus mix e d lymphoc yte re action (at conce ntrations ranging be tw e en 1 and 10 m g/ml). 3 Its inte rac tion w ith the c omple ment (Cp) syste m has so far be en found to be indire ct, by an inhibitio n of PMN re sponse tow ards compleme nt-derived chemotax ins. Our pre se nt studie s have show n that it is also capable of direc tly modulating the entire activation of Cp re ac tion c asc ade. The ex ac t mechanism for this inhibition is how e ve r, ye t to be fully ex amine d. Lysozyme, some milk proteins, such as alpha lac talbumin, and low -molec ular-w eight ligands, such as c itrates and phosphate s, are know n to have high affinity binding sites for c alc ium, 4 and may there fore act as inhibitor s of complement indire ctly, by chelating the divalent ions re quired for c omplement ac tivation. The inhibitory effe ct of lysozyme might also be re late d to its ability to degrade certain glycoprote in c ompone nts of nativ e Cp fac tors.
The se rum Cp syste m consis t of at least 19 prote ins, mostly in pre -ac tivated e nzymatic forms, activated in a multi-ste p casc ade re action via eithe r the classical or alternativ e pathw ays. The classic al pathw ay is activated mainly by antigen -antib ody c omp lex es (IgG or IgM mostly) starting w ith Clq, Clr, Cls, C4 and C2, and e ve ntually le ading to the activation of C3 by cleavage into C3a and C3b. The alternativ e pathw ay (APC) utilizes ac tive sites (such as are pre se nt on zymosan, ye as t, cobra venom, most Gram-ne gative bacte ria, shee p erythroc ytes and human c ells de ficie nt in the ex pre ssion of membrane re gulatory mole cules) in the pre senc e of prope rdin, serum factors B and D, to activate C3. This ste p unifies the tw o pathw ays and proce eds uniformly there afte r to the formation of (C5b-9) membrane attack complex es (MAC), c apable of inserting into biological me mbrane s and producing ce ll lysis and de ath. APC ac tivating surface s are charac te rize d by posse ssion of structures w hich re strict ac cess to inhibitory factor H to deposite d C3b, there by amplifying the formation of further C3b in the pre se nce of fac tor B. 
Materials and methods

Buffers
Purified human lysozyme
Purified lysozyme c rystals w as obtaine d from Serva Fe inbiochemic a-He ide lberg, Ge rmany. It w as dissolve d in SGVB 2+ and added to serum compleme nt assays in final conc entrations ranging from 50 to 1500 m g/ml. 
Sensitized sheep red blood cells
Normal human serum haemolytic assay
Serum sample s w e re obtained from 10 he althy blood donors. A micro-modification of the standard haemolytic as say w as used for the as sessme nt of serum comple ment activity. A 1: 20 dilution of serum w as pre pared, diffe re nt volumes (12.5-100 m l) of w hich w as p ipetted into the as say tube s, as w ell as 40 m l of se nsitized SRBC, to obtain a total re action volume of 375 m l, SGVB 2+ buffe r w as used for the se rum assay, inc ubating the mix ture for 60 min at 37°C, w ith occ asional mix ing. 
Assays of serum complement inhibition by lysozyme
Using the modified CH50 assay as described above , a cons tant volume of serum, c ontainin g approx mately one CH50 unit, and SRBC, w e re pipe tte d into assay tubes. Lysozyme w as added be fore inc ubation of the the re ac tion mix tures, at final conc entrations ranging from 50 to 1500 m g/ml.
Result
Lysozyme w as adde d to the serum as a source of Cp in CH50 w hole Cp as says. Conce ntrations ranging from 50 to 1500 m g/ml w ere adde d, c orre sponding to ex pe cte d physiologic al and pathological le vels of lysozyme in the colostrum, mature or inflamed breastmilk, as w ell as othe r normal and inflamed body fluids. Lysozyme w as found to inhibit the w hole se rum compleme nt activity, mainly the classic al pathw ay te ste d by CH50 assays, in a dose-depe nde nt fashion (Fig. 1) . At low c oncentration s c orre sponding to p hysiologic al levels, the inhibitory e ffec t of lysozyme w as re lative ly minimal. The inhibition there after rises sharply w ith inc re as ing c oncentration s, w ithin pathologic al ranges.
